1081 related articles for article (PubMed ID: 22049615)
41. Biology of the bone marrow microenvironment and myelodysplastic syndromes.
Rankin EB; Narla A; Park JK; Lin S; Sakamoto KM
Mol Genet Metab; 2015; 116(1-2):24-8. PubMed ID: 26210353
[TBL] [Abstract][Full Text] [Related]
42. Clonality of the stem cell compartment during evolution of myelodysplastic syndromes and other bone marrow failure syndromes.
Tiu R; Gondek L; O'Keefe C; Maciejewski JP
Leukemia; 2007 Aug; 21(8):1648-57. PubMed ID: 17554386
[TBL] [Abstract][Full Text] [Related]
43. Aging- and Senescence-associated Changes of Mesenchymal Stromal Cells in Myelodysplastic Syndromes.
Mattiucci D; Maurizi G; Leoni P; Poloni A
Cell Transplant; 2018 May; 27(5):754-764. PubMed ID: 29682980
[TBL] [Abstract][Full Text] [Related]
44. Severe hematopoietic alterations in vitro, in bone marrow transplant recipients who develop graft-versus-host disease.
Martínez-Jaramillo G; Gómez-Morales E; Sánchez-Valle E; Mayani H
J Hematother Stem Cell Res; 2001 Jun; 10(3):347-54. PubMed ID: 11454310
[TBL] [Abstract][Full Text] [Related]
45. Surface marker abnormalities in myelodysplastic syndromes.
Elghetany MT
Haematologica; 1998 Dec; 83(12):1104-15. PubMed ID: 9949628
[TBL] [Abstract][Full Text] [Related]
46. Assessment of 8-methoxypsoralen and ultraviolet a light effects on human stroma generation and function.
Legitimo A; Consolini R; Bencivelli W; Crimaldi G; Migliaccio P; Mosca F
Acta Haematol; 2006; 116(3):192-7. PubMed ID: 17016038
[TBL] [Abstract][Full Text] [Related]
47. Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome.
Carlsten M; Baumann BC; Simonsson M; Jädersten M; Forsblom AM; Hammarstedt C; Bryceson YT; Ljunggren HG; Hellström-Lindberg E; Malmberg KJ
Leukemia; 2010 Sep; 24(9):1607-16. PubMed ID: 20613786
[TBL] [Abstract][Full Text] [Related]
48. Biologic characteristics of bone marrow mesenchymal stem cells in myelodysplastic syndromes.
Kastrinaki MC; Pontikoglou C; Klaus M; Stavroulaki E; Pavlaki K; Papadaki HA
Curr Stem Cell Res Ther; 2011 Jun; 6(2):122-30. PubMed ID: 20528751
[TBL] [Abstract][Full Text] [Related]
49. Functional studies of bone marrow haemopoietic and stromal cells in the myelodysplastic syndrome (MDS).
Coutinho LH; Geary CG; Chang J; Harrison C; Testa NG
Br J Haematol; 1990 May; 75(1):16-25. PubMed ID: 2375919
[TBL] [Abstract][Full Text] [Related]
50. Pesticide induced alterations in marrow physiology and depletion of stem and stromal progenitor population: an experimental model to study the toxic effects of pesticide.
Chatterjee S; Basak P; Chaklader M; Das P; Pereira JA; Chaudhuri S; Law S
Environ Toxicol; 2014 Jan; 29(1):84-97. PubMed ID: 21987380
[TBL] [Abstract][Full Text] [Related]
51. Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?
Pleyer L; Valent P; Greil R
Int J Mol Sci; 2016 Jun; 17(7):. PubMed ID: 27355944
[TBL] [Abstract][Full Text] [Related]
52. Reserves, functional, immunoregulatory, and cytogenetic properties of bone marrow mesenchymal stem cells in patients with myelodysplastic syndromes.
Klaus M; Stavroulaki E; Kastrinaki MC; Fragioudaki P; Giannikou K; Psyllaki M; Pontikoglou C; Tsoukatou D; Mamalaki C; Papadaki HA
Stem Cells Dev; 2010 Jul; 19(7):1043-54. PubMed ID: 19788374
[TBL] [Abstract][Full Text] [Related]
53. Effects of rigosertib on the osteo-hematopoietic niche in myelodysplastic syndromes.
Balaian E; Weidner H; Wobus M; Baschant U; Jacobi A; Mies A; Bornhäuser M; Guck J; Hofbauer LC; Rauner M; Platzbecker U
Ann Hematol; 2019 Sep; 98(9):2063-2072. PubMed ID: 31312928
[TBL] [Abstract][Full Text] [Related]
54. CXCL12+ stromal cells as bone marrow niche for CD34+ hematopoietic cells and their association with disease progression in myelodysplastic syndromes.
Abe-Suzuki S; Kurata M; Abe S; Onishi I; Kirimura S; Nashimoto M; Murayama T; Hidaka M; Kitagawa M
Lab Invest; 2014 Nov; 94(11):1212-23. PubMed ID: 25199050
[TBL] [Abstract][Full Text] [Related]
55. Hematopathological alterations of major tumor suppressor cascade, vital cell cycle inhibitors and hematopoietic niche components in experimental myelodysplasia.
Chatterjee R; Gupta S; Law S
Chem Biol Interact; 2017 Aug; 273():1-10. PubMed ID: 28549617
[TBL] [Abstract][Full Text] [Related]
56. Targeting of the bone marrow microenvironment improves outcome in a murine model of myelodysplastic syndrome.
Balderman SR; Li AJ; Hoffman CM; Frisch BJ; Goodman AN; LaMere MW; Georger MA; Evans AG; Liesveld JL; Becker MW; Calvi LM
Blood; 2016 Feb; 127(5):616-25. PubMed ID: 26637787
[TBL] [Abstract][Full Text] [Related]
57. Distinct signal transduction abnormalities and erythropoietin response in bone marrow hematopoietic cell subpopulations of myelodysplastic syndrome patients.
Spinelli E; Caporale R; Buchi F; Masala E; Gozzini A; Sanna A; Sassolini F; Valencia A; Bosi A; Santini V
Clin Cancer Res; 2012 Jun; 18(11):3079-89. PubMed ID: 22496271
[TBL] [Abstract][Full Text] [Related]
58. Metabolism-related cytokine and hormone levels in the serum of patients with myelodysplastic syndromes.
Bouronikou E; Georgoulias P; Giannakoulas N; Valotassiou V; Palassopoulou M; Vassilopoulos G; Papadoulis N; Matsouka P
Acta Haematol; 2013; 130(1):27-33. PubMed ID: 23392079
[TBL] [Abstract][Full Text] [Related]
59. Stromal abnormalities in neoplastic bone marrow diseases.
Dührsen U; Hossfeld DK
Ann Hematol; 1996 Aug; 73(2):53-70. PubMed ID: 8774614
[TBL] [Abstract][Full Text] [Related]
60. [Structure and function of bone marrow environment].
Akasaka Y
Hum Cell; 1990 Oct; 3(3):193-200. PubMed ID: 2076428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
